Phaseline

Targets › LMNA

LMNA (Prelamin-A/C [Cleaved into: Lamin-A/C): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout Mar 2030.

[Lamin-A/C]: Lamins are intermediate filament proteins that assemble into a filamentous meshwork, and which constitute the major components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane. Lamins provide a framework for the nuclear envelope, bridging the nuclear envelope and chromatin, thereby playing an important role in nuclear assembly, chromatin organization,…. (UniProt, P02545)

Open in Phaseline: the race on LMNA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Nuevocor Pte.NVC-001
Gene therapy targeting LMNA mutations
LMNAPhase 1LMNA-Related Dilated CardiomyopathyMar 2030

Conditions

LMNA-Related Dilated Cardiomyopathy (1)

Modalities

other (1)

Companies

Nuevocor Pte. (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.